FDA Has Extended the Comment Period For Its Draft Biosimilar Labeling Guidance

U.S. FDA News

The FDA has extended the public comment period for its draft guidance “Labeling for Biosimilar Products: Guidance for Industry” by 60 days, to August 2, 2016:

https://www.federalregister.gov/articles/2016/06/06/2016-13223/labeling-for-biosimilar-products-draft-guidance-for-industry-availability-extension-of-comment

Download PDF

Tagged with 

Comments are closed.